Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Fig. 4

Dabrafenib- and dabrafenib+trametinib-induced SEMA6A-RhoA-YAP axis activation rescues actin cytoskeleton in BRAF-mut melanoma cells. A: BRAF-mut 2/59 and BRAF-wt ME4405 cells plated on poly-l lysine coated slides were treated or not with dabrafenib, trametinib and their combination for 48 h and 7 days, and stained with anti-YAP (green signal) and Phalloidin (red signal). The cells were counterstained with Hoechst to highlight nuclei. Scale bar 10 μm. B: Quantification of the subcellular localization of YAP from immunofluorescence of 2/59 and ME4405 cells untreated and treated with dabrafenib, trametinib and their combination for 48 h and 7 days. The results are reported as percentage of YAP expression in cytoplasmic + nuclear and nuclear fractions and at least 200 cells were counted per experiment. The results are presented as mean+/− standard deviation of three independent experiments (*p < 0.05; ** p < 0,001; *** p < 0,0001)

Back to article page